Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results.
Myriad Genetics said it is collaborating with SOPHiA GENETICS to advance a prostate cancer genomic instability score (PrGIS) with AstraZeneca, targeting clinical-trial use and potential companion diagnostic deployment via Myriad’s MyChoice CDx and SOPHiA’s decentralized platform.
Myriad Genetics and SOPHiA GENETICS said they are collaborating to advance a prostate cancer-specific genomic instability score (PrGIS) technology.
SOPHiA GENETICS and Myriad Genetics announced a new collaboration to advance prostate genomic instability score technology.